Skip to search formSkip to main contentSkip to account menu

tonapofylline

Known as: 3-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1h-purin-8-yl)bicyclo(2.2.2)oct-1- yl)propanoic Acid, Bicyclo(2.2.2)octane-1-propanoic acid, 4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1h- purin-8-yl)- 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

BG 9928

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Pharmacokinetics of Oral Tonapofylline and Its Acyl‐Glucuronide Metabolite in Patients With Mild and Moderate Hepatic Impairment
The objective of the study was to evaluate the effect of hepatic impairment on the pharmacokinetics of tonapofylline. Patients… 
2011
2011
Clinical Pharmacokinetics of Tonapofylline: Evaluation of Dose Proportionality, Oral Bioavailability, and Gender and Food Effects in Healthy Human Subjects
Tonapofylline is an antagonist of adenosine A1 receptor being developed for heart failure. In the present studies… 
2011
2011
Pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects.
OBJECTIVE The study was conducted to characterize the pharmacokinetics and pharmacodynamics of tonapofylline in subjects with… 
Review
2010
Review
2010
Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure
Importance of the field: The heart failure and cardiorenal syndromes are major public health hazards, affecting one in five… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)